首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   1047535篇
  免费   84209篇
  国内免费   2514篇
耳鼻咽喉   14780篇
儿科学   29664篇
妇产科学   28994篇
基础医学   147957篇
口腔科学   29527篇
临床医学   93037篇
内科学   204061篇
皮肤病学   19427篇
神经病学   87960篇
特种医学   41329篇
外国民族医学   184篇
外科学   165062篇
综合类   27668篇
现状与发展   4篇
一般理论   548篇
预防医学   84087篇
眼科学   24381篇
药学   77456篇
  1篇
中国医学   1908篇
肿瘤学   56223篇
  2018年   10863篇
  2016年   9574篇
  2015年   11284篇
  2014年   16491篇
  2013年   24629篇
  2012年   34116篇
  2011年   36345篇
  2010年   21006篇
  2009年   19543篇
  2008年   34526篇
  2007年   37310篇
  2006年   36742篇
  2005年   36876篇
  2004年   35819篇
  2003年   34309篇
  2002年   32879篇
  2001年   37561篇
  2000年   37829篇
  1999年   32766篇
  1998年   11724篇
  1997年   10677篇
  1996年   10432篇
  1995年   9725篇
  1994年   9269篇
  1993年   8677篇
  1992年   27754篇
  1991年   27143篇
  1990年   26555篇
  1989年   25522篇
  1988年   24137篇
  1987年   23804篇
  1986年   22626篇
  1985年   22052篇
  1984年   17680篇
  1983年   15267篇
  1982年   10429篇
  1981年   9612篇
  1980年   9020篇
  1979年   17464篇
  1978年   12970篇
  1977年   11019篇
  1976年   10054篇
  1975年   10773篇
  1974年   13242篇
  1973年   12661篇
  1972年   11927篇
  1971年   11019篇
  1970年   10520篇
  1969年   10140篇
  1968年   9086篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
11.
Two Janus-associated kinase inhibitors (JAKi) (initially ruxolitinib and, more recently, fedratinib) have been approved as treatment options for patients who have intermediate-risk and high-risk myelofibrosis (MF), with pivotal trials demonstrating improvements in spleen volume, disease symptoms, and quality of life. At the same time, however, clinical trial experiences with JAKi agents in MF have demonstrated a high frequency of discontinuations because of adverse events or progressive disease. In addition, overall survival benefits and clinical and molecular predictors of response have not been established in this population, for which the disease burden is high and treatment options are limited. Consistently poor outcomes have been documented after JAKi discontinuation, with survival durations after ruxolitinib ranging from 11 to 16 months across several studies. To address such a high unmet therapeutic need, various non-JAKi agents are being actively explored (in combination with ruxolitinib in first-line or salvage settings and/or as monotherapy in JAKi-pretreated patients) in phase 3 clinical trials, including pelabresib (a bromodomain and extraterminal domain inhibitor), navitoclax (a B-cell lymphoma 2/B-cell lymphoma 2-xL inhibitor), parsaclisib (a phosphoinositide 3-kinase inhibitor), navtemadlin (formerly KRT-232; a murine double-minute chromosome 2 inhibitor), and imetelstat (a telomerase inhibitor). The breadth of data expected from these trials will provide insight into the ability of non-JAKi treatments to modify the natural history of MF.  相似文献   
12.
13.
14.
15.
16.
17.
18.
David Marr's three-level method for completely understanding a cognitive system and the importance he attaches to the computational level are so familiar as to scarcely need repeating. Fewer seem to recognize that Marr defends his famous method by criticizing the “reductionistic approach.” This sets up a more interesting relationship between Marr and reductionism than is usually acknowledged. I argue that Marr was correct in his criticism of the reductionists of his time—they were only describing (cellular activity), not explaining (cognitive functions). But a careful metascientific account of reductionistic neuroscience over the past two decades reveals that Marr's criticisms no longer have force. Contemporary neuroscience now explains cognition directly, although in a fashion—causal-mechanistically—quite different than Marr recommended. So while Marr was correct to reject the reductionism of his day and offer an alternative method for genuinely explaining cognition, contemporary cognitive scientists now owe us a new defense of Marr's famous method and the advantages of its explanations over the type now pursued successfully in current reductionist neuroscience. There are familiar reasons for thinking that this debt will not be paid easily.  相似文献   
19.
Analyzing functional species’ characteristics (species traits) that represent physiological, life history and morphological characteristics of species help understanding the impacts of various stressors on aquatic communities at field conditions. This research aimed to study the combined effects of pesticides and other environmental factors (temperature, dissolved oxygen, dissolved organic carbon, floating macrophytes cover, phosphate, nitrite, and nitrate) on the trait modality distribution of aquatic macrofauna communities. To this purpose, a field inventory was performed in a flower bulb growing area of the Netherlands with significant variation in pesticides pressures. Macrofauna community composition, water chemistry parameters and pesticide concentrations in ditches next to flower bulb fields were determined. Trait modalities of nine traits (feeding mode, respiration mode, locomotion type, resistance form, reproduction mode, life stage, voltinism, saprobity, maximum body size) likely to indicate pesticides impacts were analyzed. According to a redundancy analysis, phosphate -and not pesticides- constituted the main factor structuring the trait modality distribution of aquatic macrofauna. The functional composition could be ascribed for 2–4 % to pesticides, and for 3–11 % to phosphate. The lack of trait responses to pesticides may indicate that species may have used alternative strategies to adapt to ambient pesticides stress. Biomass of animals exhibiting trait modalities related to feeding by predation and grazing, presence of diapause form or dormancy, reproduction by free clutches and ovoviviparity, life stage of larvae and pupa, was negatively correlated to the concentration of phosphate. Hence, despite the high pesticide pollution in the area, variation in nutrient-related stressors seems to be the dominant driver of the functional composition of aquatic macrofauna assembly in agricultural ditches.  相似文献   
20.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号